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Abstract
Mucosae-associated epithelial chemokine (MEC or CCL28) binds to CCR3 and CCR10 and recruits IgA-secreting plasma cells
(IgA-ASCs) in the mucosal lamina propria. The ability of this chemokine to enhance migration of IgA-ASCs to mucosal sites
was assessed in a mouse immunization model using HIV-1IIIB Virus-like particles (VLPs). Mice receiving either HIV-1IIIB VLPs
alone, CCL28 alone, or the irrelevant CCL19 chemokine were used as controls. Results showed a significantly increased CCR3
and CCR10 expression on CD19+ splenocytes of HIV-1IIIB VPL-CCL28-treated mice. HIV-1 Env-specific IFN-c, IL-4 and IL-5
production, total IgA, anti-Env IgA as well as gastro-intestinal mucosal IgA-secreting plasma cells were also significantly
augmented in these mice. Notably, sera and vaginal secretions from HIV-1IIIB VLP-CCL28-treated mice exhibited an
enhanced neutralizing activity against both a HIV-1/B-subtype laboratory strain and a heterologous HIV-1/C-subtype
primary isolate. These data suggest that CCL28 could be useful in enhancing the IgA immune response that will likely play a
pivotal role in prophylactic HIV vaccines.
Citation: Rainone V, Dubois G, Temchura V, U¨berla K, Clivio A, et al. (2011) CCL28 Induces Mucosal Homing of HIV-1-Specific IgA-Secreting Plasma Cells in Mice
Immunized with HIV-1 Virus-Like Particles. PLoS ONE 6(10): e26979. doi:10.1371/journal.pone.0026979
Editor: Paul A. Goepfert, University of Alabama, United States of America
Received June 8, 2011; Accepted October 7, 2011; Published October 31, 2011
Copyright:  2011 Rainone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by SIDACTION-France and the European Union program NGIN, "Next Generation HIV-1 Immunogens inducing broadly
reactive Neutralising antibodies" (Health-F3-2008-201433). The work of KU¨ was supported by the European community FP6 DEC-VAC (LSHP-CT-2005-018685) and
EUROPRISE (LSHP-CT-2006-037611) projects. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: veronica.rainone@unimi.it
Introduction
The development of prophylactic and therapeutic vaccines
against mucosal infections still represents a challenge [1,2]. IgA
secretion form mucosal tissues constitutes the first and main
adaptive immunity line of defence against such infections [3,4,5],
thus, it is conceivable that efficient prophylactic vaccines for these
infections should elicit the production of IgA. IgA-secreting plasma
blasts and plasma cells (IgA-ASCs) are characterized by a number
of surface receptor proteins, including CCR3 and CCR10, which
are bound by specific chemokines [6,7]. In particular, both CCR3
and CCR10 bind CCL28, a CC chemokine also known as
Mucosae-associated Epithelial Chemokine, or MEC [6,8,9,10].
These interactions are involved in both migration and recruitment
of IgA-ASCs into mucosal lamina propria (MLP) [4,10,11]. CCL28
is widely expressed in epithelial tissues of various mucosal sites and
it chemoattracts IgA-ASCs originated from mucosal lymphoid
organs in mucosal effector sites, including the large and small
intestine, bronchi, the mammary as well as salivary glands in both
mice and humans [4].
We recently reported a positive correlation between titers of
mucosal anti-HIV-1 IgA and the CCL28–CCR3/CCR10 system
both in HIV-1 infected and HIV-1-exposed but sero-negative
(HESN) individuals [12]. Furthermore, we demonstrated that the
recruitment of IgA-ASCs in the lamina propria is enhanced in mice
immunized with Vesicular Stomatitis Virus (VSV) in the presence
of in vivo CCL28 [12]. These observations could be important in
suggesting how to optimally build a mucosal vaccine for the
prevention of HIV infection. In this context, Virus-like Particles
(VLPs) represent a novel vaccine approach based on non-
pathogenic particles mimicking the size and the structure of the
cognate viruses [13,14,15,16]. Notably, VLPs were shown to elicit
broad immune responses in animal models and to stimulate cell
and humoral immune responses via the MHC class I and class II
antigen presentation pathways [17,18,19].
Since mucosal vaccines aim at inducing antigen-specific
secretory IgA antibodies in addition to effective cell-mediated
responses, the use of chemokines as adjuvants could significantly
improve vaccine immunogenicity and efficacy [20,21]. Chemo-
kines and their corresponding receptors are indeed the main
effector molecules of the common mucosal immune system and
are essential for regulating the homing of immune-competent cells
from the site where immune responses are induced to the mucosal
effector sites [3]. In this respect, CCL28 could represent a suitable
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candidate as mucosal molecular adjuvant. Notably, the usefulness
of CCL28 as an adjuvant for mucosal vaccination was confirmed
by recent data showing that the association of CCL28 and a DNA-
based vaccine results in the generation of a potent immune
response that prevents mucosally transmitted viral infections [22].
In the present study, we further investigate the immunomod-
ulatory effects of MEC/CCL28 in a mouse model using a prime-
boost strategy based on HIV-1IIIB-VLPs in the presence/absence
of the murine chemokine gene inserted into a CpG-free expression
vector. Results confirm the pivotal role of CCL28 in the
modulation of mucosal immunity and suggest that CCL28 could
be useful in the design of mucosal vaccines finalized at the
prevention of HIV infection.
Results
In vivo expression of CCL28 and CCL19
Inbred female Balb/c mice were immunized with a prime-boost
regime based on HIV-1IIIB VLP in the presence or in the absence
of CCL28-expressing vector. The CCL19-expressing plasmid was
used as a negative control. This chemokine was chosen because,
similarly to CCL28, it plays a crucial role in lymphoid cell
trafficking but nevertheless it does not have an effect on IgA+
plasma cells; additionally, CCL19 does not bind CCR3 or CCR10
but rather uses CCR7. To verify if pCCL28 and pCCL19 were
effective expression vectors and whether their use resulted in
systemic increases of the corresponding chemokines, CCL28 an
CCL19 were measured in immune sera. Results showed a
significant increase in serum CCL28 levels of HIV-VLPIIIB-
CCL28 and CCL28 alone mice compared to HIV-VLPIIIB-
CCL19, HIV-VLPIIIB, CCL19 alone and saline mice (p,0.01 in
all cases). Similar results were observed when serum CCL19 levels
from both HIV-VLPIIIB-CCL19 and CCL19 alone mice were
compared to those obtained in HIV-VLPIIIB-CCL28, HIV-
VLPIIIB, CCL28 alone or saline animals (p,0.03 in all cases)
(Fig. 1).
CCR3- and CCR10- expressing CD19+ cells
To analyze the expression of chemokine receptors on circulating
lymphocytes, CCR3- and CCR10-expressing CD3+, CD14+ and
CD19+ splenocytes were analyzed in all mice. Results showed that
CD19+/CCR3+ and CD19+/CCR10+ splenocytes were signifi-
cantly augmented in HIV-VLPIIIB-CCL28 treated mice as
compared to HIV-VLPIIIB-CCL19 (p = 0.014 and 0.043, respec-
tively), HIV-VLPIIIB alone (p = 0.005 and 0.006, respectively),
CCL28 alone (p = 0.005 and 0.008, respectively), CCL19 alone
(p = 0.002 and 0.005, respectively), and saline control mice
(p = 0.001 and 0.004, respectively) (Fig. 2A and 2B). CD19+/
CCR3+ and CD19+/CCR10+ cells were also augmented, although
not in a statistically significant manner, in both HIV-VLPIIIB-
CCL19 and HIV-VLPIIIB alone groups of animals as compared to
control groups. However, these results were not completely
unexpected, because the use of VLP-based vaccine strategies have
been shown to effectively activate both arms of the immune
response and a direct and/or an indirect effect on lymphocyte
phenotype cannot be excluded. In contrast with these results,
CCR3 and CCR10 expression was comparable in CD3+
splenocytes and CD14+ cells of all groups (data not shown).
Surface density of CCR3 and CCR10 on CD19+ cells
Evaluation of mean fluorescence intensity (MFI) showed that
the CCR3 MFI on CD19+ splenocytes was significantly augment-
ed in HIV-VLPIIIB-CCL28 treated mice compared to HIV-
VLPIIIB-CCL19 (p = 0.029), HIV-VLPIIIB alone (p = 0.015),
CCL28 alone (p = 0.012), CCL19 alone (p = 0.009), or saline
control mice (p = 0.005) (Fig. 2C). CCR10 MFI on CD19+
lymphocytes was similarly upregulated in HIV-VLPIIIB-CCL28
treated mice compared to all the other groups (Fig. 2D).
Cytokine production by HIV-1/Env-stimulated splenic
and colon cells
Splenic and colonic cells were restimulated with recombinant
HIV-1IIIB/Env-gp120 to quantify Th1-type (IFN-c) and Th2-type
(IL-4 and IL-5) cytokines production. Results showed a significant
increase of IFN-c production by both spleen and PP/colonic cells
from HIV-VLPIIIB-CCL28-treated mice as compared to mice
receiving either HIV-VLPIIIB-CCL19 (spleen p = 0.034; colon
p = 0.041) or VLP alone (spleen p = 0.026; colon p = 0.033)
(Fig. 3A). A significant increase of IL-4 and IL-5 production was
observed as well in HIV-VLPIIIB-CCL28-treated mice compared
with either HIV-VLPIIIB-CCL19 (spleen p = 0.048 and 0.043;
colon p = 0.040 and 0.011) or VLP alone animals (spleen p = 0.002
Figure 1. In vivo expression of recombinant CCL28 and CCL19. Panels A and B respectively represent concentrations (pg/ml) of CCL28 and
CCL19 in sera from each mice group immunized with: HIV-1-VLPIIIB-CCL28, HIV-1-VLPIIIB-CCL19, HIV-1-VLPIIIB, CCL28 alone, CCL19 alone and control
(saline) at days 0 (T0), 14 (T1) and 28 (T2). The data are expressed as mean6 SD (n = 5 mice per group) of three independent experiments. Statistically
significant differences are shown.
doi:10.1371/journal.pone.0026979.g001
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and 0.001; colon p = 0.01 and ,0.001) (Fig. 3B and 3C). In
contrast, and as expected, anti-HIV-1/Env-gp120 responses were
not observed either in pre-immune mice or in the mice group-
treated with CCL28 alone, CCL19 alone, or saline.
HIV-1/Env gp120-specific systemic humoral response
Serum was collected two weeks after the final immunization to
measure Env-specific antibodies; ELISA were performed on
microwell plates coated with HIV-1IIIB Env gp120. Results
showed that serum Env-specific IgG and IgA were increased in
HIV-VLPIIIB-CCL28 mice compared to HIV-VLPIIIB-CCL19
(p = 0.05 and 0.046) or HIV-VLPIIIB mice (p = 0.042 and 0.04)
(Fig. 4). Env-specific antibodies were not observed in pre-immune
mice, CCL28 alone, CCL19 alone, and saline animals.
Total and HIV-specific mucosal IgA
To assess CCL28-induced migration of Ig-ASCs at mucosal
sites, both total and Env-specific antibody responses were
Figure 2. Analysis of CCR3 and CCR10 receptor expression on CD19+ B splenocytes. Percentage of CCR3-expressing CD19+ splenocytes
(A), percentage of CCR10-expressing CD19+ splenocytes (B). Flow cytometry analysis of expression of the CCR3 receptor (C) or CCR10 receptor (D) at
the surface of CD19+ splenocytes (MFI). Data represents three different lots of independent experiments. Mean values 6 SD and statistically
significant differences between each immunized mice group and the reference HIV-1-VLPIIIB-CCL28 group are indicated. CCR3 expression on B-cells
examined by flow cytometry (E). For each analysis, 20000 events were acquired and gated on CD19 expression and side scatter properties. The cells
were stained with anti-CCR3 monoclonal antibody, as described in Materials and Methods. The percentages of CCR3+ cells are indicated in Results.
The data are from a single representative experiment of three similar experiments performed for freshly isolated CD19+ splenocytes.
doi:10.1371/journal.pone.0026979.g002
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quantified in vaginal secretions of immunized and control mice.
Total IgA levels were significantly augmented in vaginal secretions
of HIV-VLPIIIB-CCL28-treated mice compared to all other
animals (vs. VLPIIIB-CCL19 p = 0.04, vs. VLPIIIB alone
p = 0.008, vs. CCL28 alone, CCL19 alone, and saline p,0.001,)
(Fig. 5A). Notably, Env-specific IgA levels were significantly
increased as well in vaginal secretions of HIV-VLPIIIB-CCL28
mice compared to HIV-VLPIIIB-CCL19 and HIV-VLPIIIB alone
animals (p = 0.045 and p = 0.005, respectively) (Fig. 5B).
Neutralization activity of sera and mucosal secretions
To verify whether the use of CCL28 would result in an
enhanced neutralizing activity of Env-specific antibodies, neutral-
ization experiments using pooled sera against HIV-1IIIB and HIV-
1DU174 were performed. Two different virus strains were used:
HIV-1IIIB, a subtype B CXCR4-tropic strain, and HIV-1DU174, a
subtype C CCR5-tropic strain. A marginal (,15%) neutralizing
activity was detected in the pre-immune and immune sera of mice
treated with either CCL28 alone, CCL19 alone, or saline (data not
shown). Immune sera from HIV-VLPIIIB-CCL28 treated mice
showed a neutralization activity titer of 220 and 160 (50%
neutralization activity) against, respectively, HIV-1IIIB at a
TCID50 of 40 and HIV-1DU174 at a TCID50 of 20 (Fig. 6A
and 6C). Conversely, immune sera from HIV-VLPIIIB-CCL19 or
VLPIIIB alone mice showed a neutralization activity titer of 100
against HIV-1IIIB and of 80 against HIV-1DU174 at the same
TCID50 of 40 and 20, respectively (Fig. 6A and 6C).
Immune vaginal secretions from HIV-VLPIIIB-CCL28-receiv-
ing mice showed a neutralization titer of 80 and 40 against,
respectively, HIV-1IIIB and HIV-1DU174 (Fig. 6B and 6D). Also in
this case the neutralization activity against both strains was lower
in mice treated with HIV-VLPIIIB-CCL19 or VLPIIIB alone mice,
resulting in a neutralizing titer of 46 and 18, respectively. No
neutralization activity was present when HIV-1IIIB and HIV-
1DU174 were used at a double TCID50 (data not shown).
The neutralization observed against both a clade B and a clade
C virus with vaginal secretions is apparently puzzling considering
that antibody concentration in vaginal secretions is lower than in
serum. A technical issue with VLP-based vaccines is their tendency
to elicit anti-cell antibodies against non-Env membrane proteins
that could interfere with the neutralization assays [23]. Hence in
traditional assays, such as the PBMC-based neutralization assay,
controls are used to identify possible non-specific activity. We
employed a HIV-2CLB-20 neutralization assay as a control to
Figure 3. HIV-specific cell-mediated responses. HIV-specific cytokine production in HIV-1-VLPIIIB-CCL28, HIV-1-VLPIIIB-CCL19, HIV-1-VLPIIIB,
CCL28 alone, CCL19 alone and control (saline)-treated mice is shown. Panels A, B, and C respectively represent IFN-c, IL-4 and IL-5 concentrations (pg/
ml) in the supernatants from ex vivo HIV-1IIIB/gp120-restimulated splenic and PP/colonic cells. Mean values (mock subtracted) 6 SD and statistically
significant differences are represented.
doi:10.1371/journal.pone.0026979.g003
CCL28 and Mucosal Immunity
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26979
distinguish anti-Env activity from non-specific effects. Neutraliza-
tion activity of murine samples against HIV-2CLB-20 was marginal
(,25%) suggesting that both sera and vaginal secretions of
immunized mice are indeed endowed with anti-Env reactivity
(Fig. 6E and 6F).
Furthermore, to verify whether the results could be a
consequence of changes in cell viability, HIV-1IIIB- and HIV-
1DU174-infected PBMCs that were either untreated or mixed with
matched serum and vaginal secretions were stained with 7-AAD.
As shown in Fig. 7, the viability of HIV-1IIIB- and HIV-1DU174-
infected PBMCs was not significantly affected by incubation with
either murine sera or vaginal secretions, as the presence of
apoptotic and/or necrotic cells could be related to the direct
cytopathic effect of the viruses. Of note, the small amount of cell
death observed in HIV-VLPIIIB-CCL28 treated mice was below
the background level of apoptosis detected in tissue culture as
indicated by the levels of viability observed in untreated uninfected
PBMCs.
Finally, in order to determine the relative contribution of the
main antibody isotypes to the neutralizing activity of vaginal
secretions, IgA, IgG or IgA + IgG immune absorption experiments
were performed. Results clearly showed that IgA antibodies from
VLP-immunized mice played a major role in the neutralization of
both HIV-1IIIB and HIV-1DU174 and that IgA-mediated neutral-
ization activity was enhanced in a CCL28-dependent manner. In
the absence of CCL28, but in the presence of VLP alone or in
combination with CCL19, the neutralization level was lower and
mostly IgG-dependent. Nevertheless, this was confirmed by the
observation that, along with depletion of both IgA and IgG
antibodies, the neutralization activity was almost abolished (Fig. 8).
Figure 4. Anti-HIV-1 systemic humoral immunity. The anti-HIV-1 antibody production in mouse sera is shown at days 0 (T0), 14 (T1 and 28 (T2)
from each of the following immunized mice groups: HIV-1-VLPIIIB-CCL28, HIV-1-VLPIIIB-CCL19, HIV-1-VLPIIIB, CCL28 alone, CCL19 alone and control
(saline)-treated mice. Levels of anti-HIV-1/Env-specific IgG (A) and anti-HIV-1/Env-specific IgA (B) in sera. The data are expressed as the mean 6 SD
(n = 5 mice per group) from three independent experiments. Statistically significant differences between groups and the reference HIV-1-VLPIIIB-
CCL28 group are indicated.
doi:10.1371/journal.pone.0026979.g004
Figure 5. Anti-HIV-1 humoral immunity in mucosal sites. Mucosal anti-HIV-1 antibody production at days 0 (T0), 14 (T1) and 28 (T2) is
represented for the following group of immunized mice: HIV-1-VLPIIIB-CCL28, HIV-1-VLPIIIB-CCL19, HIV-1-VLPIIIB, CCL28 alone, CCL19 alone and control
(saline)-treated mice. Total (A) and anti-Env (B) IgA levels present in vaginal secretions. The data represent mean values6 SD (n = 5 mice per group) of
three independent experiments. Statistically significant differences compared to the HIV-1-VLPIIIB-CCL28 group are represented.
doi:10.1371/journal.pone.0026979.g005
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Figure 6. Mouse sero-neutralization activity against HIV-1 or HIV-2. Experiments were run on pooled sera from HIV-1-VLPIIIB-CCL28, HIV-1-
VLPIIIB-CCL19, HIV-1-VLPIIIB, or control (saline)-treated mice. Upper panels show ex vivo neutralizing activity against HIV-1IIIB of immune sera (A) or
CCL28 and Mucosal Immunity
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Results demonstrated the significant IgA contribution to the
observed non-IgG-mediated neutralization of both HIV-1 clades,
although not completely excluding the possible minor roles of other
Ig subclasses.
IgA+ plasma cells in the gastro-intestinal mucosal lamina
propria
Since the GI MLP is the principal site of HIV replication during
primary infection the induction of virus-specific- mucosal immunity
would be beneficial as it could obstacle the establishment of infection.
As the results herein demonstrated that the up-regulation of CCL28-
CCR3/CCR10 circuit is correlated with increased concentrations of
both systemic and mucosal HIV-specific IgA, we analyzed IgA-ASC
distribution in the GI mucosal lamina propria. IgA+ plasma cells were
clearly identified by immunopositive staining in the cytoplasm of cells
with plasma cell-like morphology. Results showed the presence of
numerous IgA+ cells clustered within the lamina propria of the colonic
mucosa in HIV-VLPIIIB-CCL28 mice. The number of IgA
+ plasma
cells observed in the colonic MLP of these mice was significantly
higher compared to all the other groups of mice (p,0.001), in whom
only rare and isolated IgA+ cells could be identified. Representative
results are shown in Fig. 9. The higher frequency of IgA-ASCs in the
gastrointestinal mucosa of HIV-1-VLPIIIB-CCL28 mice group as
compared with the CCL28 alone group is not surprising, as it could
be directly related to the induction of antigen-specific humoral
immunity. Exposure to HIV-1IIIB VLPs indeed leads to activation of
naı¨ve B-cell clones specific for HIV-1 antigens that then undergo
clonal expansion, mitotically forming large populations of cells
including memory cells and antibody-secreting plasma cells. Thus
administration of the murine CCL28 gene-expressing vector to HIV-
1-VLPIIIB mice would result in a large influx of both polyclonal and
antigen-specific IgA-ASCs to the mucosa.
Discussion
The vast majority of newly acquired HIV infections are sexually
transmitted. In this modality of infection the virus initially targets
Figure 7. Cell viability. Experiments were run on pooled sera of HIV-1-VLPIIIB-CCL28, HIV-VLPIIIB-CCL19 and HIV-VLPIIIB-treated mice. Upper panels
show the percentage of cell death in HIV-1IIIB-infected PBMCs mixed with 2-fold serial dilutions of murine sera (A) or vaginal washes (B) 7 days post-
infection. Lower panels show the percentage of cell death in HIV-1DU174-infected PBMCs mixed with 2-fold dilutions of murine sera (C) or vaginal
washes (D) 7 days post-infection. Cell survival was measured by 7-AAD staining and flow cytometry analysis. HIV-1IIIB or HIV-1DU174-infected PBMCs
and untreated uninfected PBMCs were used, respectively, as positive and negative controls. Data represents three different lots of independent
experiments.
doi:10.1371/journal.pone.0026979.g007
vaginal secretions (B). Middle panels show ex vivo neutralizing activity against HIV-1DU174 of immune sera (C) or vaginal secretions (D). Lower panels
show ex vivo neutralization activities against HIV-2CLB-20, respectively from immune sera and vaginal secretions (E, F). The neutralization titer of
immune sera and of vaginal secretions is represented as percentages of the virus replication as compared with control samples. Dotted line indicates
50% neutralizing activity. A pool of three neutralizing anti-HIV-1 monoclonal antibodies (IgG1b12, 2F5 and 2G12, termed TriMab) was serially diluted
at 2-fold dilutions, starting from 50 mg/ml to 1.56 mg/ml, and was used as a positive control in the neutralization assay against HIV-1IIIB and HIV-
1DU174. Data represent three different lots of independent experiments.
doi:10.1371/journal.pone.0026979.g006
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the vaginal or rectal mucosa; preventative vaccines or microbicides
should thus be designed to protect such mucosae [24,25]. With the
exception of the moderately promising results of the RV144 trial
(the so called ‘‘Thai trial’’) [26,27,28], no candidate HIV-1 vaccine
has shown convincing successful results. Alternate approaches
based on the prevention of HIV infection through the use of
topical microbicides have also exhibited unsatisfactory results [29],
even if very recently promising breakthrough results were
presented [30]. Therefore, strategies to protect mucosal tissues,
including vaccines designed to play protective and therapeutic
roles via the elicitation of systemic immune responses, are needed.
To better understand how to construct a mucosal vaccine that
could protect the tissues that are the earlier targets of HIV
infection, we focused on CCL28, a chemokine that plays an
important role in the migration of IgA-ASC in the mucosal lamina
propria [7].
Results presented herein demonstrate that immunization of
mice with Env-expressing VLPs in the presence of CCL28 results
in the modulation of the whole CCL28-CCR3/CCR10 circuit
and optimizes immunization-induced HIV-specific immune re-
sponse. Thus, cytokine secretion by spleen and colon cells, as well
as total and HIV-specific IgA and IgA+ plasma cells were
significantly increased in the presence of CCL28. Notably, HIV-
specific IgA and IgG titers were significantly increased in serum as
well, suggesting that, systemic as well as mucosal immune
responses are efficiently modulated by CCL28. Finally, the
observation that the neutralization ability of serum and vaginal
washes of immunized mice in the presence of CCL28 was
Figure 8. HIV-1 neutralization of Ig-depleted mucosal secretions. Experiments were run on pooled IgG- or IgA- or IgG/IgA-depleted vaginal
secretions from HIV-1-VLPIIIB-CCL28, HIV-1-VLPIIIB-CCL19, HIV-1-VLPIIIB mice. Upper panel show ex vivo neutralizing activity against HIV-1IIIB of immune
vaginal secretions (A). Lower panels shows ex vivo neutralizing activity against HIV-1DU174 of immune vaginal secretions (B). The neutralization titer is
represented as percentages of the virus replication as compared with control samples. Dotted line indicates 50% neutralizing activity. The data
represent the results of two duplicate-sample assays.
doi:10.1371/journal.pone.0026979.g008
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increased indicates that the immune modulation induced by this
chemokine is associated with an augmented capacity to down-
modulate HIV infectivity.
This study shows that the objective of up-regulating potentially
beneficial mucosal immune responses is achievable, at least in the
mouse model, by CCL28. Our results demonstrate that CCL28
indeed results in the recruitment of IgA-ASCs in mucosal
epithelial tissues and this effect is associated with an increased
neutralization activity. The increased neutralization ability toward
at least two different HIV clades exhibiting the two major X4 and
R5 tropisms, detected in immune sera and vaginal secretions,
indicates that the reduction of HIV infectivity in vivo could be
achieved by such adjuvant.
The tissue-targeted lymphocyte migration is strongly regulated
by a complex network of chemokines [9]. CCL28 has been shown
to govern the ASC homing, and in particular that of IgA-ASCs to
gastro-intestinal tissues, upper aero-digestive and mammary glands
[31]. CCL28 binds to CCR3 and CCR10 and CCR10 is
considered to be a unifying chemokine receptor playing a pivotal
role in plasma blasts homing of extra-intestinal effector sites [8,32].
The ability of the CCL28-CCR3/CCR10 circuit to chemoattract
ASCs into multiple mucosal sites has indeed been a founding
Figure 9. CCL28 effect on colon IgA-ASCs. IgA+ plasma cell distribution at the mucosal level in BALB/c mice immunized with HIV-1-VLPIIIB-CCL28
(A), HIV-1-VLPIIIB-CCL19 (B), HIV-1-VLPIIIB alone (C), CCL28 alone (D), CCL19 alone (E) and saline (F) is shown. Representative results obtained in the
lamina propria of colonic mucosa (2-cm specimens from the anus toward the left colon) are presented. Quantitation of IgA-ASCs in colon specimens
(G). The sum of 12 high-power fields was calculated for each mouse and data are expressed as means of this sum 6 SD for each group.
doi:10.1371/journal.pone.0026979.g009
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element of the concept of a common mucosal immune system.
Recent results indicate that CCL28 has a broad and unifying role
in the IgA physiology of the mucosal immune system [33,34].
IgA are mostly mucosal antibodies involved in the first line of
defense of adaptive immunity facing pathogens. The anti-HIV-1
mucosal IgA are not only observed in HIV-1 infected individuals
[35,36], but also have been detected in some, and not in all HIV-
exposed seronegative individuals (HESN) [37,38,39]. IgA isolated
from cervico-vaginal secretions of these individuals are capable of
inhibiting virus transcytosis through epithelial layers in vitro and
have a potent neutralizing activity [40,41,42]. Because IgA from
HESN seem to contribute to the prevention of infection of these
individuals, it is reasonable to infer that vaccine procedures
capable of eliciting a massive IgA response would be beneficial by
contributing to the containment of HIV-1 infection.
The gut-associated lymphoid tissue (GALT) contains the
majority of T-cells in the body; recent data showed that GALT
is the preferential target for HIV replication during the acute
phase of HIV infection [43,44]. These observations have
strengthened the need for mucosal vaccine for the prevention of
HIV infection [45,46]. Results presented here indicate that
CCL28 significantly increases the quantity of mucosal ASCs in
the colon as well. Although in this study we did not directly
measured rectal IgA, it is plausible that increased quantity of tissue
IgA-producing ASCs would results in an increased amount of
secreted antibodies, thus the situation of IgA in rectal washes
would parallel what is observed in vaginal washes of CCL28-
receiving mice.
In this study we report that intramuscular administration of
HIV-1IIIB-VLPs in the presence of the CCL28-expressing plasmid
correlates with a robust up-regulation of chemokine receptor
expression on circulating B-cells and an increase in both systemic
and mucosal immunity. This could apparently be surprising, as
parenteral immunization is generally thought not to induce
significant immune responses at mucosal surfaces. However,
recent studies have revealed the possibility of cross-talk between
systemic compartments and mucosal tissues [47,48,49]. Further-
more, CCL28 was shown to be constitutively expressed by bone
marrow stromal cells, suggesting a role for this chemokine in the
integration between the mucosal and the systemic immune
responses through interaction with CCR10+/CCR3+ circulating
B-cells [7]. It is tempting to speculate that the enhanced expression
of CCL28 in the draining lymph nodes following vaccination
would upregulate CCR3 and CCR10 in locally recruited CD19+/
CCR3+ and CD19+/CCR10+ cells. Activated antigen-specific B-
cells generated in draining lymph nodes could disseminate to
GALT, as CCR3 and CCR10 would allow their trafficking to
mucosal tissue sites that constitutively express CCL28. Following
homing to GALT, activated lymphocytes would undergo prefer-
ential isotype switching to IgA under the influence of cytokines
such as IL-4, IL-5 or IL-10. This hypothesis is supported by the
observation that Th2 cytokine responses were augmented in the
GALT of mice treated with HIV-1IIIB-VLPs in the presence of
CCL28. Alternatively, CCR10+ dendritic cells capable of
presenting HIV-specific peptides could traffic from draining
lymph nodes to Peyer’s patches and mesenteric lymph nodes
and initiate the production of antigen-specific IgA-ASCs that
would subsequently home to the lamina propria of GALT. It is
conceivable that CCL28 may function not only as chemoattrac-
tant but also as a co-activator, as the level of systemic antibody and
cytokine would not be greatly affected, although the mechanisms
underlying the induction of antigen-specific cellular and humoral
responses at both the systemic and mucosal level needs to be
further investigated.
As far as the CCL28-CCR3/CCR10 circuit is concerned, the
percentage of CD19+/CCR3+ cells was unexpectedly high as
compared with previous results observed in humans [12]. To date,
CCR3 expression on B-cells and the biological functions of the
CCR3 ligand CCL28 for murine B-cells have not been
characterized. In humans, besides being expressed in eosinophils,
basophils and dendritic cells [50], CCR3 has been shown to be
selectively expressed in T helper 2 (Th2) cells [51] and in
antibody-secreting plasma blasts and plasma cells [6,7]. If this
observation holds true also for the mouse system, the expression of
CCL28 in the lymph nodes draining the site of vaccine inoculation
would result in a more efficient recruitment of CD19+/CCR3+
cells, providing a plausible basis for B-cell activation and clonal
expansion upon encounter with vaccine antigens. Subsequently,
lymphocyte recirculation between tissues and blood compartments
would account for the high frequency of CD19+/CCR3+
splenocytes observed in the mouse model. However, it should
also be taken into account the source of B-cells used for the flow
cytometric analyses, as CCR3 has been shown to be virtually
absent on freshly isolated human peripheral B-cells [52], while it
has been detected in mouse spleen and liver [53,54,55].
Nevertheless, further work needs to be done to establish the
expression of CCR3 on murine B-cells and the role of this receptor
in the CCL28-mediated lymphocyte homing.
It is noteworthy that results showed significant differences in the
plasmid-induced serum levels between CCL28 and CCL19 in vivo,
although pCCL28 and pCCL19 contained the same murine
Cytomegalovirus (CMV) promoter and no substantial differences
were observed in the in vitro production of CCL28 and CCL19 by
HEK/293T-cells (data not shown). However, taking into account
the physiological variation in normal serum levels between these
two chemokines in the mouse model, only the increase in CCL28
but not in CCL19 production from baseline resulted in an
enhanced immune response in HIV-1-VLPIIIB treated mice after
administration of the chemokine expression plasmid. Taken
together our data allow us to speculate that the higher adjuvant
efficacy of pCCL28 than pCCL19 is not related to the variability
in the plasmid-induced chemokine production but to the different
mechanism of action of the encoded chemokine, CCL28 recruiting
IgA-ASCs to mucosal effector sites and CCL19 directing T-cell
and DC migration to lymphoid organ T zones.
In conclusion, we show that CCL28 used as an adjuvant has a
robust immunomodulatory effect on potentially beneficial mucosal
and systemic immune responses. Notably, the beneficial immuno-
modulatory effects of CCL28 is not likely limited to HIV infection
as this chemokine was recently shown to be effective in eliciting
long-lived antibody responses that neutralized influenza A/PR8/
34 and protected mice from morbidity and mortality associated
with a lethal intranasal viral challenge [22]. These findings suggest
that CCL28 could play a useful role in increasing the efficiency of
preventive vaccines for HIV infection.
Materials and Methods
Production of HIV-1IIIB VLP
HIV-1 virus like particles (VLP) were produced by transient
transfection of HEK/293T-cells (human embryo kidney carcino-
ma cell-line, T clone) (Sigma-Aldrich, Germany) with the plasmids
pCD-Hgpsyn and pConBgp160-opt. pCD-Hgpsyn containing the
codon-optimized gag-pol sequence of HIV-1IIIB kindly provided
by Geneart (Regensburg, Germany). pConBgp160-opt encodes a
consensus full-length HIV-1/subtype B (HIV-1/B) envelope
obtained from the AIDS Research and Reference Reagent
Program, Division of AIDS, NIH, (Dr. Beatrice Hahn). Conflu-
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ence of 80–90%, HEK/293T cells were transfected with 40 mg of
each plasmid in DMEM medium supplemented with PEI [10 mg/
ml], 5% FCS and penicillin/streptomycin. The transfection
medium was changed 18 hr after transfection with DMEM medium
supplemented with 2% FCS and penicillin/streptomycin and
harvested 48 hr later. The harvested medium was centrifuged at
3006g for 10 min and filtered through a 0.45 mm filter to remove
cell debris. VLP were further purified and concentrated from the
conditioned medium by ultracentrifugation through a 20% sucrose
gradient and a subsequent ultracentrifugation at 28,000 rpm for
2 hr a SW28 rotor (Beckman, CA). Supernatants were discarded
and the pellets containing viral particles were resuspended in PBS.
The endotoxin level was measured by QCL-1000H Chromogenic
LAL Endpoint Assay (Cambrex, Germany) according to the
manufacturer’s instructions. The concentration of viral proteins in
the final VLP preparation was determined by an in-house ELISA
and corresponded to 1.5 mg/ml of HIV-1 Env and 0.55 mg/ml of
HIV-1 Gag. The calibration curve was set up by using recombinant
HIV-1IIIB Env gp120 (Baculovirus) (EVA607 supplied by the
NIBSC centralized facility for AIDS Reagents supported by EVA
EU Program) and Gagpr55 (AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH).
Production of chemokine-expressing plasmids
The MEC/CCL28 murine chemokine gene was digested with
AgeI from the pORF-mCCL28 plasmid (InvivoGen, San Diego,
CA) and a blunt end was produced with T4-DNA polymerase.
Following digestion with NheI, the resulting 410 bp fragment was
inserted into a pCpG expression vector, previously digested with
ScaI/NheI. The CCL19/MIP-3b murine gene from the pORF5-
mMIP3b inserted into a pCpG expression vector (InvivoGen, San
Diego, CA) as described above was used as a negative control. The
endotoxin level was measured by QCL-1000H Chromogenic LAL
Endpoint Assay (Cambrex, Germany) according to the manufac-
turer’s instructions.
Immunization procedures
The study was approved by the Italian Ministry of Health
(Permit Number: 02/010) and animals were managed according
to the principles of the "Guide for the Care and Use of Laboratory
Animals" and in accordance with the Italian national law
(Legislative Decree. 116/1992) and the recommendations of the
European Community (86/609/CEE) for the care and use of
laboratory animals. Adult inbred female Balb/c mice, 6–8 weeks
old, were purchased from Charles River Laboratories (Calco,
Italy). Mouse colonies were maintained on a 12-h light-dark cycle
in cages of 5 animals with water and food provided ad libitum. Mice
were randomized in six groups (5 mice/group) to receive: HIV-
1IIIB VLP (150 ng Env/mouse) in combination with the murine
CCL28 gene inserted into a CpG-free expressing plasmid
(pCCL28) (50 mg/mouse) or HIV-1IIIB VLP in combination with
the murine CCL19 gene also inserted into a CpG-free expressing
plasmid (pCCL19) (50 mg/mouse) or HIV-1IIIB VLP alone
(150 ng Env/mouse) or pCCL28 alone (50 mg/mouse) or pCCL19
alone (50 mg/mouse). Control mice were treated with endotoxin-
free phosphate-buffered saline (PBS, Organon Teknika Corp.,
Durham, NC). HIV-1IIIB VLP, pCCL28 and pCCL19 were
administrated intramuscularly in quadriceps muscles. Mice were
immunized on day 0, boosted on day 14 and sacrificed by cervical
dislocation on day 28.
Blood and vaginal secretion collection
Fifty microliters of blood were collected by tail vein bleeding and
added to 100 ml of phosphate-buffered saline (PBS, Organon
Teknika Corp.) containing 100 IU of heparin (Hip-PBS, Sigma).
Serum was obtained after centrifugation at 800 g for 10 min and
stored at -80uC. Vaginal secretions were collected with 50 ml of pre-
warmed PBS supplemented with 100X-concentrated protease
inhibitor cocktail (1%, v/v) (O-complete, Roche Applied Science,
Germany) by repeated aspiration until a discrete quantity of mucus
was recovered. Material was collected and centrifuged at 12,000 g
for 10 min, the supernatant was transferred to sterile microcen-
trifuge tubes and frozen at 220uC until use. The endotoxin level
was measured by QCL-1000H Chromogenic LAL Endpoint Assay
(Cambrex, Germany) in both sera and vaginal secretions according
to the manufacturer’s instructions, resulting in a an endotoxin
concentration of 0.8 ng/ml and 0.4 ng/ml, respectively.
Tissue harvesting
Mice were anesthetized for 2 min with ether gas and sacrificed
by neck dislocation. Spleens were excised under sterile conditions
in a laminar flow hood and put through a 100 mm plastic strainer
(BD Falcon 2350, BD Biosciences, Bedford, MA) for cell recovery.
Splenocytes were layered on a continuous 40–100% Percoll
gradient (Sigma) and washed twice in PBS to obtain lymphocyte-
rich cells. Cell viability was determined using Trypan blue
staining. Splenocytes were resuspended in cell culture medium
(RPMI 1640) (Organon Teknika Corp.) and used in cell culture
assays. Peyer’s patches (PP)/colonic mononuclear cells were
recovered from freshly obtained specimens. Colon specimens
were first washed in HBSS-with Phenol Red (BioWhittaker Inc.,
Walkersville, MD) cut into 0.5-cm pieces. They were then
incubated twice, each time for 15 min in 0.37 mg/ml EDTA-
HBSS (Sigma) and 0.145 mg/ml dithiothreitol (Thermo Fisher
Scientific, Rockford, IL) at 37uC. Tissues were further digested at
37uC for 10 min with 400 U/ml of Collagenase D (Roche) and
0.01 mg/ml of DNase I (Sigma). Tissue-released cells were
suspended in a continuous 100%–40% Percoll gradient to obtain
the lymphocyte-enriched population. Mice recta were also
analyzed by immune-histochemistry.
Cell count
Cell count was performed with the automated cell counter
ADAM-MC (Digital Bio, NanoEnTek Inc, Korea). ADAM-MC
automatic cell counter measures total cell numbers and cell
viabilities by cutting-edge detection technologies. In addition to
Trypan blue staining, ADAM-MC procedure was carried out using
two sensitive fluorescence dye staining solutions, AccuStain Solution
T (Propidium Iodide/lysis solution) and AccuStain Solution N
(Propidium IodideI/PBS). AccuStain Solution T permeabilizes
plasma membrane stain nucleus that allow measurements of total
cell enumeration, while AccuStain Solution N exclusively stains
non-viable cells. A 532 nm optic laser is automatically focused onto
the cell suspension contained into a disposable microchip where cell
analysis is made with a CDD camera.
CCL28 and CCL19 expression in vivo
In vivo expression of active CCL28 and CCL19 chemokines in
serum samples encoded by the plasmids was verified using
commercial ELISA kits (R&D Systems, Minneapolis, MN) and
following the manufacturers’ instructions. Chemokine concentra-
tion was calculated from a standard curve obtained with the
corresponding recombinant mouse chemokine.
Flow cytometry analysis of CCR3 or CCR10 expression
CCR3 or CCR10 receptor expression was evaluated on
splenocytes. Cells were resuspended in PBS and their surface
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stained with mAbs CD3e PE- Cy5 (Armenian Hamster IgG isotype,
eBioscience, San Diego, CA), anti-mouse CD14 PE-C-conjugated
Cy5 (rat IgG2a isotype, eBioscience), PE-Cy5-conjugated anti-
mouse CD19 (rat IgG2a isotype, eBioscience), a rat FITC-
conjugated anti-mouse CCR3 IgG2a isotype (R&D Systems,
Minneapolis, MN), and a rat anti-mouse CCR10 PE IgG2b isotype
(R&D Systems). Following incubation 15 min at room temperature
in the dark, cells were washed 3 times in PBS and fixed in 1%
formaldehyde. All the cytometric analyses were performed using an
FC500 flow cytometer (Beckman-Coulter, Miami, FL) equipped
with a double 15-mW argon ion laser operating at 456 and 488
interfaced with an Intercorp (Venice, Italy) computer. For each
analysis 20,000 events were acquired and gated on CD3 or CD14 or
CD19 expression and side scatter properties. Green fluorescence
from FITC (FL1) was collected through a 525-nm band-pass filter,
orangered fluorescence from R-PE (FL2) was collected through a
575-nm bandpass filter and red fluorescence from Cy5PE (FL4) was
collected through a 670-nm band-pass filter. Data were collected
using linear amplifiers for forward and side scatter and logarithmic
amplifiers for FL1, FL2, FL4, and FL5.
Cytokine assays
IFN-c, IL-4 and IL-5 production were measured in the
supernatants from splenocytes as well as in PP/colonic T cells
after ex vivo re-stimulation with recombinant HIV-1IIIB/Env gp120
(NIBSC) using commercial ELISA kits (R&D Systems) and
following manufacturers’ procedures.
Evaluation of humoral immune responses
Anti-HIV-IgG and IgA were measured in sera and vaginal
secretions by an ELISA method based on a recombinant HIV-1
envelope protein. 96 well ELISA plates were coated overnight at
4uC with 100 ml of 4 mg/ml recombinant HIV-1IIIB Env gp120
(Baculo) (NIBSC). Plates were washed three times with PBS-
Tween-20 0.05% buffer, and incubated for 2 hr at 37uC, 5% CO2
with PBS containing 3% of Bovine Serum Albumin (BSA) (Sigma,
St Louis, MO) to block non-specific protein binding sites. Serum
dilutions 1/10 to 1/10000 and vaginal wash dilutions 1/2 to 1/
1000 were incubated for 2 hr at 37uC, 5% CO2. Plates were then
washed three times and a goat HRP-conjugated anti- a-chain IgA
antibody mouse (Sigma) or a goat HRP-conjugated anti-mouse
IgG antibody (Jackson Immuno-Research, West Grove, PA)
diluted 1:1000 or 1:30000 in PBS/BSA respectively was added
to the plates. Following 1 h of incubation at 37uC, 5% CO2, the
plates were washed and incubated with tetramethylbenzidine
(TMB, R&D Systems) substrate solution for 30 min at RT. The
addition H2SO4 1.8 M stopped the colour reaction. IgG or S-IgA
concentrations were measured at an Optical density absorbance
l= OD490. Total IgA from vaginal secretions were measured by
ELISA as described above, excepting the coating that was carried
out at 4uC overnight with 100 ml of a goat anti-mouse IgA
antibody (Kamiya Biomedical Company, Seattle, WA). Sample
concentrations were determined from standard curves, using
purified Ig standard mouse IgA and IgG (Sigma) assayed in
parallel; values were expressed in nanograms per milliliter.
Ig depletion of vaginal secretions
Streptococcal protein G and Staphilococcal protein A were used
to specifically remove IgG and/or IgA from mucosal samples.
Mouse vaginal secretions were diluted 1:2 with RPMI 1640 medium
(Organon Teknika Corp.) supplemented with 1% penicillin/
streptomycin and incubated with an equal volume of Sepharose-
immobilized recombinant protein G (PGS) and/or Sepharose-
immobilized recombinant protein A (PAS) (Sigma Chemical Co.,
St. Louis, MO). The incubation was carried out for 2 h at 37uC with
constant gentle rotation to prevent sedimentation of the PGS and/
or the PAS. After centrifugation for 2 min at 1000 g, the
supernatant was withdrawn and incubated for 12 h on the rotator
at 4uC with a second aliquot of PGS and/or PAS equal to the first.
The specimens were then returned to the 37uC rotating incubator
for an additional 2 h. After centrifugation at 1000g for 2 min, the
1:2 diluted vaginal washes, either IgG-depleted or IgA-depleted or
IgG/IgA-depleted, were harvested.
HIV-1 neutralization assay
HIV-1 neutralization assay was performed in a pooled donor
PBMC-based assay. Briefly, pooled sera from pre-immunized and
immunized mice were complement-depleted by heat inactivation
at 56uC for 60 min and serially diluted at 2-fold dilutions, starting
from 1/20. Pooled vaginal secretions were serially diluted at 2-fold
dilutions, starting from 1/10. Vaginal secretions were assayed
before and after Ig depletion. Sera and vaginal secretions were
incubated in a humidified 5% CO2 incubator at 37uC for 60 min
in duplicate in 96-well plates with the laboratory strain HIV-1IIIB
and the primary isolate HIV-1DU174 (NIBSC) of 40 and 20
TCID50, respectively. One hundred thousand PBMCs pooled
from HIV-negative donors were stimulated with PHA for 48 hr,
added to each well, and incubated overnight (18 hr) at 37uC. Cells
were extensively washed with RPMI 1640 (Organon Teknika
Corp.), centrifuged at 400 g for 10 min and fresh medium (RPMI
1640, 200 mM L-glutamine, 20% fetal calf serum, 10 U IL-2, 1%
penicillin and 2% streptomycin) was replaced on day 1 and day 3.
After 7 days, supernatants were harvested and p24 antigen levels
were determined by ELISA according to the manufacturer’s
instructions (Perkin-Elmer, Waltham, MA). Five hundred thou-
sand uninfected and infected PBMCs either not treated or mixed
with matched serum and vaginal secretion dilutions from
immunized mice were also stained with 7-AAD viability dye
(Beckman Coulter) to test cell toxicity of murine samples. After
20 min incubation at room temperature, cells were centrifuged at
800 g for 10 min in PBS and analyzed by flow cytometry. HIV-
2CLB-20 (NIBSC) neutralization assay was performed in a PBMC-
based assay to identify non-specific activity of murine samples and
the protein p27 was detected by ELISA according to the
manufacturer’s instructions (ZeptoMetrix Corp., NY).
Immunohistochemistry analyses
Tissues obtained from the colon of mice (2-cm specimens from
the anus toward the left colon) were fixed in 10% buffered-
formalin for 24 hr at room temperature and embedded in paraffin.
Haematoxylin-eosin stained sections were used for histological
evaluation. The evaluation of IgA+ plasma cells was made on
3 mm paraffin embedded slides, the sections were dewaxed in
xylene, rehydrated in an ascendent ethanol scale and pre-treated
in a microwave oven (two cycles for 5 minutes each at 780 W, in
EDTA buffer, pH 8). Endogen biotin and non-specific signals
were blocked with appropriated reagents. For immuno-histochem-
istry, a goat anti-mouse IgA (dilution 1:400, AbD Serotec) was
used, slides were incubated for 2 hr at room temperature in a
humid chamber, washed in PBS, and revealed by biotinylated
anti-goat IgG (dilution 1:50, 1 hr incubation, R&D Systems,
London, UK) followed by HRP-Conjugated Streptavidin (30 min
incubation, R&D Systems, London, UK). The chromogen was 3,
39-diaminobenzidine free base (DAB).
Statistical analysis
Comparisons between groups were analyzed to evaluate
immunological differences. Kruskaal-Wallis analysis of variance
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was performed for each variable; Bonferroni correction was applied
to the results. Two-sided p-values were considered. Data analysis was
performed using the SPSS statistical package (SPSS Inc. Chicago, IL).
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